Bryan Johnson's Dog and the Real Science of Canine Longevity Research

On 20 August 2026, biotech entrepreneur Bryan Johnson, known for his heavily documented and heavily criticised human anti-aging regimen, adopted a Belgian Malinois puppy named Katara. He framed the adoption as part of his longevity thinking, citing a statistic that dog owners have roughly a 24 percent lower risk of dying early than non-owners.

That number is real. It comes from a peer-reviewed meta-analysis, not something invented for social media. But the number is also easy to misread, and the gap between what the research says and what a headline implies is exactly the kind of thing worth slowing down for.

The 24 percent figure comes from Kramer, Mehmood and Suen, a systematic review and meta-analysis published in Circulation: Cardiovascular Quality and Outcomes in 2019, which pooled data across multiple observational studies on dog ownership and human mortality.

The finding is an association, not a controlled experiment. People who own dogs tend to walk more, keep more regular routines, and in some studies report more social contact, all of which independently correlate with longer life. The dog may be a marker of an already active, socially connected lifestyle as much as a cause of one. The authors of the meta-analysis themselves frame it as a signal worth further study, not proof that acquiring a dog adds years to a life.

Setting the marketing angle aside, dogs are a genuinely useful model for human aging research, for reasons that have nothing to do with any individual owner's habits. Dogs share the human indoor and outdoor environment, are exposed to many of the same pollutants and lifestyle factors, receive a comparable standard of veterinary medical care to human healthcare in many countries, and develop many of the same age-related diseases people do, including cancer, cognitive decline and heart disease.

Crucially, dogs live roughly a seventh as long as people. A study that would take 30 or 40 years to run in humans can plausibly be run in dogs within 5 to 10 years. This is the premise behind the Dog Aging Project, a large-scale, US National Institute on Aging funded research consortium described in a 2022 paper in Nature, which is following tens of thousands of companion dogs and collecting survey data, veterinary records, genetic sequencing and biological samples to understand what actually predicts healthy versus unhealthy aging in a real, genetically diverse population living in ordinary homes.

The specific drug most associated with dog longevity research is rapamycin, a compound that inhibits a cellular growth pathway called mTOR and has extended lifespan in multiple laboratory species, including mice, worms and flies. It has also been used off-label in some human longevity clinics for decades, largely as an immunosuppressant to prevent organ-transplant rejection, at doses far higher than what has been tested for aging. In 2017, a team from the University of Washington, publishing in GeroScience, ran the first randomised controlled trial testing a much lower dose of rapamycin in companion dogs rather than laboratory animals, a meaningful step because pet dogs live in ordinary homes, eat ordinary food and are exposed to ordinary environmental stressors, unlike inbred laboratory mice kept in controlled facilities.

Twenty four healthy, middle-aged dogs received either a placebo or a low, non-immunosuppressive dose of rapamycin for 10 weeks. The result: no significant clinical side effects in the treated dogs compared with placebo, and echocardiogram measurements suggested improvement in several age-related markers of heart function, including the E over A ratio, fractional shortening and ejection fraction.

This is a genuinely interesting early signal. It is not evidence that rapamycin extends a dog's life. The trial was small, short, measured heart-function markers rather than lifespan or healthspan, and has not been independently replicated. The study's own authors describe it as the basis for testing rapamycin in a larger cohort over a longer period, which is exactly what happened next.

The Test of Rapamycin in Aging Dogs, known as TRIAD, is the follow-up study built to settle what the 2017 pilot could only suggest. Its design was published in GeroScience in 2025: a prospective, parallel-group, double-masked, randomised, placebo-controlled, multicenter trial recruiting healthy, middle-aged dogs from the wider Dog Aging Project cohort, run across multiple US veterinary schools with lifespan and healthspan metrics as its actual endpoints.

It is worth being precise about what this means. The 2025 publication is a study-design and rationale paper, not a results paper. As of the most recent published description, TRIAD had not yet reported outcome data. Its authors describe it as the first rigorous test of a pharmacological anti-aging intervention with lifespan and healthspan as endpoints to be conducted outside a laboratory, in any species. When results eventually arrive, they will be the closest thing geroscience has to a real answer on whether rapamycin does what the 2017 pilot hinted at.

Running in parallel to the academic research is Loyal, a California-based company founded specifically to develop a lifespan-extension drug for dogs and, eventually, license the same regulatory playbook toward human aging. Its lead candidate, a prescription drug called LOY-002, is aimed specifically at senior dogs. Rather than targeting a single disease, LOY-002 is designed to act on age-related metabolic changes that gradually raise the risk of multiple conditions as dogs get older, with the stated goal of slowing the biological processes that make older dogs' bodies more fragile over time, rather than treating any one illness after it appears.

LOY-002 has moved further through the US regulatory system than any other lifespan-extension drug for any species. The FDA's Center for Veterinary Medicine has already accepted Loyal's Reasonable Expectation of Effectiveness data, and as of August 2026 has also accepted its Target Animal Safety data, the second of three major technical sections. The remaining hurdle is a manufacturing review, after which Loyal intends to apply for Expanded Conditional Approval. If it succeeds, LOY-002 would become the first FDA-approved drug intended to extend lifespan itself, in any species, human or animal. It would be a daily prescription pill aimed at dogs aged 10 and older weighing at least 14 pounds, still contingent on completing its ongoing clinical trial and further FDA review.

The reason this matters beyond dog owners is translational. If a real, adequately powered trial in dogs can show that a drug extends healthy lifespan on a timescale of years rather than decades, it becomes a genuine data point for whether the same mechanism is worth testing in people, something human geroscience trials cannot easily produce on their own given how long humans live. A 40-year human trial of a single drug is not something any research funder or pharmaceutical company can practically run. A dog trial with a comparable biological question can, in principle, produce an answer within a single researcher's career.

That is a meaningfully different claim from Bryan Johnson's dog-ownership statistic, which is about companionship and lifestyle, not pharmacology. The rapamycin-in-dogs research and the dog-ownership-and-mortality research are two separate bodies of evidence that happen to have collided in the same news cycle because of one adopted puppy. Conflating them, treating a lifestyle-association study and a drug-mechanism study as if they support the same conclusion, is a common pattern in longevity media coverage generally, and worth flagging every time it happens, on this site or anywhere else.

None of this should be read as an endorsement of the wider claims sometimes made around dog longevity, or of rapamycin as something a person should be sourcing for themselves or their pet outside a supervised clinical trial. The 2017 pilot trial was funded and run by researchers affiliated with the Dog Aging Project, several of whom have since taken advisory or founder roles at longevity-focused companies, a conflict of interest worth knowing about even when the underlying data appears sound. Small early trials in any field of medicine have a well-documented tendency to show more promising results than larger follow-up trials eventually confirm, and geroscience is not exempt from that pattern.

The honest state of play is that dog longevity research is a genuinely active, well-funded, methodologically serious field, not a fringe topic, but it is still years away from a confirmed answer on whether any drug extends a dog's healthy lifespan, let alone a human's. Treating a single adopted puppy and a single meta-analysis as proof of anything overstates what either can support.

Taken together, where this actually stands as of August 2026: a real, published, peer-reviewed observational association between dog ownership and lower human mortality risk, with the usual limits of observational data. A real, small, short, peer-reviewed pilot trial suggesting rapamycin is well tolerated in dogs and may improve heart-function markers, not yet proof of a longer life. A large, well-designed multicenter trial specifically built to test the lifespan question, still running, with no results published yet. And a company, Loyal, closer than anyone to regulatory approval for a lifespan-extension drug in any species, still short of full approval.

Nothing described here is available to buy, prescribe or administer in Ireland, and none of it is something a person can act on for their own dog today. Gerovia does not list veterinary or pet-longevity providers and has no plans to. This piece exists because the underlying science, and what the current evidence does and does not show, is worth understanding on its own terms.